Vir Biotechnology (NASDAQ:VIR) Q2 results:
Revenues: $67.0M (+999%). Increase mainly due to GSK and Brii agreements.
Net loss: ($31.2M); loss/share: ($0.27).
Upcoming milestones:
Phase 2/3 study of VIR-7831, a SARS-CoV-2 neutralizing antibody, to launch this month with preliminary data expected before year-end.
Phase 2 study of another SARS-CoV-2 neutralizing antibody, VIR-7832, to launch later this year.
Preclinical studies of VIR-2703, an inhaled SARS-CoV-2-targeting small interfering ribonucleic acid, to be completed by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.